Kineta Presents New Preclinical Data on its Lead VISTA Antagonist Antibody at the AACR Annual Meeting 2021 Seattle, WA -- (April 12, 2021) Kineta, Inc., a clinical stage biotechnology company focused ...

Kineta Receives Regulatory Approval for Initiation of Phase 1 Clinical Trials of KCP506 First in-human clinical trials will evaluate the safety and pharmacokinetics of a first-in-class α9α10 nicotini ...

Kineta to Present at the Upcoming 2020 Solebury Trout  Virtual Investor Conference Seattle, WA -- (March 24, 2020) Kineta, Inc., a clinical stage biotechnology company focused on the development of ...

Kineta Invited to Participate at the Cowen and Company 40th Annual Health Care Conference Seattle, WA -- (February 26, 2020) Kineta, Inc., a clinical stage biotechnology company focused on the develo ...

Kineta Invited to Participate at the BIO CEO & Investor Conference Seattle, WA -- (February 5, 2020) Kineta, Inc., a clinical stage biotechnology company focused on the development of novel immun ...